News

Xerava has been developed for the treatment of cIAI in patients 18 years of age and older. In clinical trials, Xerava has showed statistical non-inferiority to two widely

The company has secured approval from the Food and Drug Administration for drugs with strengths of 3 mg/0.02 mg/0.451 mg and 0.451 mg (EQ Beyaz). Lupin’s Drospirenone, Ethinyl

CogniCann is one of MXC’s medical cannabis pharmaceutical products with a THC:CBD ratio specifically formulated to treat key Dementia symptoms and enhance specific cognitive functions. The approval was

The EU approval is based on data from the COMPASS study, the largest phase III study with rivaroxaban (27,395 patients), which showed that the rivaroxaban vascular dose, 2.5mg

HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of edema (swelling) in various parts of the body. Hereditary Angioedema Association president

The agreement will not include South Korea where JWP will retain its exclusivity over the JW1601 drug, which was developed by one of its affiliates – C&C Research

Gritstone Oncology will leverage its proprietary EDGE artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets

M Ventures, the strategic, corporate venture arm of Merck KGaA, Darmstadt, Germany, and existing investors provided an additional $4m in the company’s Series A. Concurrent with the financing,

In the trial, Bevespi Aerosphere, a rival COPD treatment to GSK’s product, showed non-inferiority to umeclidinium/vilanterol on peak forced expiratory volume in one second (FEV1) but and failed